Liquid Biopsy for Precision Oncology East Coast on June 26-27, 2025 in Boston, United States

The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda, sharpened focus, and a renewed mission: to accelerate access to more sensitive, less invasive testing by addressing the most pressing challenges across the entire patient care continuum.

Bringing together leaders in Biomarker Development, Translational Research, Diagnostics, Clinical Development, Pathology, and beyond, this is the go-to East Coast forum for diving deep into the barriers slowing the adoption of liquid biopsy technologies.

Take home actionable insights to ensure you're maximizing the value of liquid biopsies in your therapeutic development strategies. Shape the future of precision oncology, and be part of the conversations that will drive meaningful change for patients worldwide.

URLs:

Tickets: https://go.evvnt.com/2973730-2?pid=10008

Brochure: https://go.evvnt.com/2973730-3?pid=10008

Time: 7:50 AM - 4:35 PM

Prices:

Drug Developers and Researchers - *Free: USD 0.50,

Solution Providers - On The Door: USD 3799.00

Speakers: Brian Dougherty, Director - Global Genomics and Translational Medicine Oncology, AstraZeneca, Duane Hassane, Head of Translational Omics, Hematology R AND D, AstraZeneca, Emily Chan, Executive Director – Oncology Global Development, Amgen, Joshua Levin, Director, Precision Medicine and Digital Health, GlaxoSmithKline, Minakshi Guha, Associate Director, LBx Strategy, Precision and Translational Medicine, Takeda Pharmaceutical, Radha Ramesh, Associate Director - Clinical Biomarker Lead - Oncology, Takeda Pharmaceutical, Raluca Predoiu, Director - Companion Diagnostic Strategy Lead, Abbvie, Supriya Shah, Director - Oncology Precision Medicine, Johnson and Johnson, David Wurtman, Chief Business Officer, Geneos Therapeutics, Inc., Ella Aguado, Associate Director - Translational Medicine, Repare Therapeutics, Haifa Ghandour, Associate Director - Diagnostic Lead, Alexion Pharma UK, John Boyce, President and CEO, BrickBio, Qing Li, Director, Pathology, Clinical Development, Oncology, Moderna, Carolina Reduzzi, Associate Professor and Director of Liquid Biopsies, Weill Cornell Medicine,, David Westenberg, Managing Director, Piper Sandler Companies, Jean Lopategui, Professor of Pathology, Cedars-Sinai Medical Center, Lauren Houghtalin, Director, Disease State, Technical Sales, BioIVT, Lauren Leiman, Executive Director, BloodPAC, Marina Milan, Project Manager, FNIH